Research Progress in Hepatocyte Growth Factor/Mesenchymal-epithelial Transition Factor Signaling Pathway:Effects and Mechanisms on Resistance to Targeted Therapy for Non-small Cell Lung Cancer / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
; (6): 259-264, 2021.
Article
in Zh
| WPRIM
| ID: wpr-878729
Responsible library:
WPRO
ABSTRACT
Targeted therapy is an important therapeutic method for advanced non-small cell lung cancer with driver gene alteration.However,resistance to targeted therapy will inevitably happen in clinical practice,which has become a major issue demanding prompt solution.Studies have demonstrated that bypass resistance mediated by the activation of hepatocyte growth factor(HGF)/mesenchymal-epithelial transition factor(MET)signaling pathway is a common cause of resistance to targeted therapy.Presently,relevant studies have accumulated rich experience in the specific mechanisms.To be brief,HGF/MET is an important target for overcoming the resistance to targeted therapy and promises to be a leading biomarker for judging and observing the occurrence of resistance.This paper introduces the recent studies concerning the effects and mechanisms of HGF/MET signaling pathway on resistance to targeted therapy.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Signal Transduction
/
Hepatocyte Growth Factor
/
Carcinoma, Non-Small-Cell Lung
/
Proto-Oncogene Proteins c-met
/
Epithelial-Mesenchymal Transition
/
Lung Neoplasms
Limits:
Humans
Language:
Zh
Journal:
Acta Academiae Medicinae Sinicae
Year:
2021
Type:
Article